Revium Rx. Solidifies Leadership with Permanent CEO, New Chairman Focused on Capital & M&A

summarizeSummary

Revium Rx. has appointed Amir Avraham as its permanent CEO and Shlomi Schwartzblat as Chairman, with significant performance incentives tied to securing new equity investments and M&A transactions, addressing the company's critical need for capital.

check_boxKey Events

• Permanent CEO Appointed

  Amir Avraham, previously interim CEO, has been appointed as the permanent Chief Executive Officer, effective February 1, 2026. His compensation includes a monthly salary of NIS 55,000, an annual discretionary bonus, and a one-time $50,000 cash bonus upon completion of $5 million in new equity investments.

• New Chairman of the Board Appointed

  Shlomi Schwartzblat has been appointed as a Director and Chairman of the Board. Mr. Schwartzblat brings extensive experience in investments, business development, and managing early-stage investment firms, which is highly relevant for the company's strategic needs.

• Performance-Based Equity Incentives

  The CEO will receive an initial grant of 1,300,000 stock options, with additional grants of 300,000 options tied to securing $3 million in accumulated investments and another 300,000 options upon the successful completion of an M&A transaction. These incentives directly align leadership with critical capital raising and strategic objectives.

auto_awesomeAnalysis

This 8-K filing is highly significant for Revium Rx., a company that recently disclosed substantial doubt about its ability to continue as a going concern. The appointment of Amir Avraham as permanent Chief Executive Officer, following his interim role, provides crucial leadership stability. More importantly, his compensation package includes substantial stock options and a cash bonus directly contingent on the completion of new equity investments totaling $5 million and $3 million respectively, and a successful M&A transaction. These incentives are strategically aligned with the company's urgent need to raise capital and explore strategic alternatives. The simultaneous appointment of Shlomi Schwartzblat as Chairman of the Board further strengthens the company's strategic capabilities. Mr. Schwartzblat's extensive background in investments, business development, and managing early-stage investment firms positions him well to guide Revium Rx. through its financing challenges and potential M&A activities. These leadership changes and performance-based incentives represent a proactive and critical step by the company to address its financial viability and secure its future.